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AMP-activated protein kinase (AMPK) regulates cellular metabolism in response to available energy at both
the cellular and whole-body levels. In this issue, McBride et al. (2009) show that AMPK is inhibited by
glycogen, adding another tier to its regulation and suggesting that it can act as a glycogen sensor.AMP-activated protein kinase (AMPK) has
been described as a cellular fuel gauge
responding to a decrease in intracellular
ATP levels by altering cell metabolism,
switching on energy-providing pathways,
and switching off energy-consuming
pathways. At the single-cell level, AMPK
therefore acts as an energy sensor, allow-
ing the cell to meet the challenge of
increased energy demand or reduced
energy supply. More recently, AMPK has
been shown to play an important role in
energy homeostasis at the whole-body
level and to be regulated by hormones
such as leptin, adiponectin, ciliary neuro-
trophic factor, and ghrelin (Kahn et al.,
2005). Activation of AMPK in the liver
has been shown to be essential for the
glucose-lowering effect of metformin
(Shaw et al., 2005), a drug that is widely
used as a treatment in type 2 diabetes.
Consequently, AMPK offers an attractive
target for drugs aimed at treatment of
the metabolic syndrome. In the current
issue, a new study by McBride et al.
(2009) reports that AMPK can be regu-
lated directly by glycogen and may act
as a glycogen sensor.
AMPK is activated primarily by phos-
phorylation of threonine 172 (T172) within
the catalytic a subunit of the heterotri-
meric kinase complex, and in the absence
of T172 phosphorylation, AMPK is essen-
tially inactive (Kahn et al., 2005). Several
protein kinases have been identified
that phosphorylate T172, although
most of the evidence to date implicates
LKB1 and calcium/calmodulin-depen-
dent protein kinase kinase b (CaMKKb)
as the major upstream kinases acting on
AMPK in vivo. In the past few years the
regulation of AMPK phosphorylation has
been examined in detail. A key mecha-
nistic issue has been to understand how
an increase in the AMP:ATP ratio withinthe cell leads to increased T172 phos-
phorylation. Initially, it was proposed that
AMP could directly activate the upstream
kinases, but this has subsequently
been discounted (Sanders et al., 2007).
Instead, it appears that binding of AMP
to the g subunit renders T172 a worse
substrate for dephosphorylation by
protein phosphatases. Despite the recent
elucidation of the structure of the
mammalian g subunit in complex with
either AMP or ATP (Xiao et al., 2007), the
molecular basis for the protection of
dephosphorylation of T172 remains enig-
matic. In addition to phosphorylation,
AMPK is activated allosterically by AMP.
The degree of activation is small in
comparison to the effect of phosphoryla-
tion, varying between 2- and 5-fold,
depending on the nature of the subunit
isoforms within the complex (Cheung
et al., 2000).
Now, following the study by McBride
et al. published in this issue, we can add
yet another mode of regulation to AMPK.
The authors show that glycogen allosteri-
cally inhibits AMPK. While this finding is
exciting, it is perhaps not too surprising.
Several years ago, two groups simulta-
neously identified a domain present in
the b subunit of AMPK that allows binding
of the kinase to glycogen (Hudson
et al., 2003; Polekhina et al., 2003). This
domain had previously been identified as
an N-isoamylase domain, present in
enzymes that metabolize the a1/6
linked branch points in starch and
glycogen, and in AMPK the domain was
subsequently termed the glycogen-
binding domain (GBD). This observation
was tantalizing because several previous
studies had linked AMPK to glycogen
metabolism. AMPK phosphorylates and
inactivates glycogen synthase (Carling
and Hardie, 1989), whereas high levelsCell Metabolisof glycogen in skeletal muscle correlate
with lower activation of AMPK in response
to exercise (Wojtaszewski et al., 2003).
More significantly, at least from a clinical
standpoint, naturally occurring mutations
within the g2 subunit cause a severe
glycogen storage cardiomyopathy in hu-
mans, associated with ventricular pre-ex-
citation (Arad et al., 2007). Although there
is still some controversy surrounding the
exact effects of the mutations, it is now
generally accepted that the mutations
increase the basal activity of AMPK while
reducing or abolishing activation by AMP
in vitro. The perplexing issue here, of
course, is that these mutations occur in
the g subunit, quite distinct from the
GBD-containing b subunit.
The present study is provocative
because it provides a missing link in the
chain between glycogen, the GBD of
AMPK, and kinase activity. McBride et al.
(2009) show that glycogen allosterically
inhibits AMPK by a mechanism that
requires the presence of the GBD.
Through a series of experiments the
authors further demonstrate that oligo-
saccharides containing an a1/6 linkage
are more potent allosteric inhibitors than
linear a1/4 linked oligosaccharides.
This finding may have significant phy-
siological implications related to the
structure of glycogen present in the cell:
the more branched the glycogen the
more potent an inhibitor of AMPK it would
become. This might explain some of the
previous observations, including the
finding that glycogen synthase is dephos-
phorylated and active following a bout of
exercise. According to theauthors’model,
exercise would lead to degradation of
glycogen, exposingmorebranches, inhib-
iting AMPK, and allowing activation of
glycogen synthase (following dephos-
phorylation by protein phosphatase-1).m 9, January 7, 2009 ª2009 Elsevier Inc. 7
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branching in glycogen in hearts from
transgenic mice expressing mutant g2
was reported tobe lowerdespite amarked
decrease in AMPK activity (Davies et al.,
2006). Clearly, further studies will be
required to determine the effect of
glycogencontent anddegreeof branching
on AMPK activity in vivo.
In addition to allosteric inhibition,
McBride et al. report that the branched
oligosaccharide inhibited T172 phosphor-
ylation by either LKB1 or CaMKKb but
did not affect dephosphorylation. The
branched oligosaccharide did not directly
inhibit LKB1, implying that inhibition of
T172 phosphorylation is mediated by
binding of the oligosaccharide to AMPK.
It will be important to determine whether
the presence of the GBD is required for
this effect, or whether some other part of
the AMPK molecule is involved. Paradox-
ically, previous work in yeast revealed that
the GBD plays a role in regulating SNF1,
the S. cerevisiae homolog of AMPK, inde-
pendently of glycogen (Momcilovic et al.,
2008). It remains to be determined howStructure of Full-L
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The first crystal structure of a full-le
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The recently reported crystal structure of
a full-length nuclear receptor complex on
DNA (Chandra et al., 2008) represents
a long-awaited and significant step for-
ward on the way to understanding struc-
ture-function relationships for this impor-
tant family of transcription regulators.
Nuclear receptors (NR) control multiple
physiological phenomena (i.e., embryo-
genesis, cell growth, and apoptosis). As
8 Cell Metabolism 9, January 7, 2009 ª2009theGBD in SNF1 regulates kinase activity,
for instance whether some other molecule
binds to the domain and whether this
might also be the case with mammalian
AMPK. The new study raises a number
of questions: Does glycogen inhibit
AMPK in vivo and, if so, what is the effect
of glycogen branching on inhibition? Do
other oligosaccharides regulate AMPK?
What is the molecular basis for the allo-
steric inhibition of AMPK and decrease
in T172 phosphorylation by glycogen?
Given the dynamism in the field, it is likely
that we will not have to wait too long for
the answers to emerge.
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that harbors the ligand-dependent activa-
tion function (AF2) is also highly conserved
but to a lesser extent. The other two
domains are variable both in length and
sequence. The hinge region constitutes
a small domain of 30–50 amino acids that
links the DBD and LBD. Finally, there is the
N-terminal AB domain, whose size ranges
from 20 amino acids in Vitamin D Receptor
toover 600 in the steroid ligands subfamily.
